<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811027</url>
  </required_header>
  <id_info>
    <org_study_id>TACTI-003</org_study_id>
    <secondary_id>Keynote- PNC-34</secondary_id>
    <nct_id>NCT04811027</nct_id>
  </id_info>
  <brief_title>Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC</brief_title>
  <acronym>TACTI-003</acronym>
  <official_title>TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immutep S.A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immutep S.A.S.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab&#xD;
      against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with PD-L1 positive&#xD;
      (CPS ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients&#xD;
      with PD-L1 negative tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 154 patients will be recruited in the TACTI-003 (Two ACTive Immunotherapies) Phase IIb&#xD;
      study which will take place across several countries in Australia, Europe and United States&#xD;
      of America in up to 35 experienced clinical sites. It will evaluate the safety and efficacy&#xD;
      of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st&#xD;
      line metastatic or recurrent HNSCC with PD-L1 positive (CPS ≥1) tumors, and determine the&#xD;
      efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors.&#xD;
      Subjects in cohort A (CPS ≥1) will be randomized 1:1 to receive either &quot;P+E&quot;: efti plus&#xD;
      pembrolizumab or &quot;P only&quot;: pembrolizumab alone. Subjects in cohort B (CPS &lt;1) will receive a&#xD;
      combination of efti and pembrolizumab &quot;P+E&quot;. Efti will be administered for up to 24 months&#xD;
      using a 30 mg s.c. dosing every 2 or 3 weeks. Pembrolizumab will be administered for up to 24&#xD;
      months using a 400mg i.v. (30 min) dosing every 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) according to RECIST1.1</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) according to iRECIST</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to and duration of responses according to iRECIST and RECIST 1.1</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate according to iRECIST and RECIST 1.1</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) according to iRECIST and RECIST 1.1</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-efti-specific antibodies</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of (serious) adverse events</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of (serious) adverse events</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of (serious) adverse events</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using EORTC QLQ-H&amp;N35</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>At Screening: three weeks prior to cycle 1 day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Circulating level of TH1 biomarker</measure>
    <time_frame>Up to 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of biomarkers or other characteristics with any efficacy or safety endpoint</measure>
    <time_frame>Up to 24 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>(CPS ≥1): Pembro + Efti</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).&#xD;
Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(CPS ≥1): Pembro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(CPS &lt;1): Pembro + Efti</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).&#xD;
Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eftilagimod alpha</intervention_name>
    <description>APC activator, MHC II agonist, LAG-3 fusion protein</description>
    <arm_group_label>(CPS &lt;1): Pembro + Efti</arm_group_label>
    <arm_group_label>(CPS ≥1): Pembro + Efti</arm_group_label>
    <other_name>IMP321</other_name>
    <other_name>Efti</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>anti-PD-1 antibody</description>
    <arm_group_label>(CPS &lt;1): Pembro + Efti</arm_group_label>
    <arm_group_label>(CPS ≥1): Pembro</arm_group_label>
    <arm_group_label>(CPS ≥1): Pembro + Efti</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Histologically- or cytologically-confirmed recurrent disease not amenable to curative&#xD;
             treatment with local or systemic therapy, or metastatic (disseminated) HNSCC of the&#xD;
             oral cavity, oropharynx, hypopharynx, or larynx that is considered incurable by local&#xD;
             therapies and to be treated in the first line palliative setting and who are PD-X&#xD;
             naïve.&#xD;
&#xD;
          2. Availability of tissue for PD-L1 biomarker analysis from a core or excisional biopsy.&#xD;
&#xD;
          3. Availability of PD-L1 biomarker result by using the FDA approved Dako standardized&#xD;
             diagnostic test (PD-L1 IHC 22C3 pharmDx).&#xD;
&#xD;
          4. Availability of tissue for testing of human papillomavirus (HPV) status for&#xD;
             oropharyngeal cancer (p16 expression testing).&#xD;
&#xD;
          5. ECOG performance status 0-1.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Disease is suitable for local therapy administered with curative intent.&#xD;
&#xD;
          2. Previously treated with ≥ 1 systemic regimen for recurrent and/or metastatic disease&#xD;
             (with the exception of systemic therapy completed &gt;6 months prior if given as part of&#xD;
             multimodal treatment for locally advanced disease).&#xD;
&#xD;
          3. Histologically or cytologically confirmed head and neck cancer of any other primary&#xD;
             anatomic location in the head and neck not specified in the inclusion criteria&#xD;
             including subjects with HNSCC of unknown primary, squamous cell carcinoma originating&#xD;
             from skin, or non-squamous histologies (e.g. nasopharynx, salivary gland or mucosal&#xD;
             melanoma).&#xD;
&#xD;
          4. Has progressive disease (PD) within 6 months of completion of curatively intended&#xD;
             systemic treatment for locoregionally advanced HNSCC.&#xD;
&#xD;
          5. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic&#xD;
             T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).&#xD;
&#xD;
          6. Has received prior chemotherapy, anti-cancer monoclonal antibody, major surgery,&#xD;
             another systemic cancer therapy or has participated in a trial of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to cycle 1 day 1.&#xD;
&#xD;
          7. Known active central nervous system metastasis and/or carcinomatous meningitis.&#xD;
             Subjects with previously treated brain metastases may participate provided they are&#xD;
             radiologically stable: i.e. without evidence of progression documented by repeat&#xD;
             imaging performed after therapy completed for CNS metastasis and with at least 4 weeks&#xD;
             difference, clinically stable and without requirement for steroid treatment for at&#xD;
             least 14 days prior to cycle 1 day 1.&#xD;
&#xD;
          8. Receives continuous systemic treatment with either corticosteroids (&gt;10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 7 days prior to&#xD;
             cycle 1 day 1. Inhaled or topical steroids and physiological replacement doses of up&#xD;
             to 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             auto-immune disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frederic Triebel</last_name>
    <phone>+33660916539</phone>
    <email>frederic.triebel@immutep.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Peguero, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine Llc</name>
      <address>
        <city>Kapitanivka</city>
        <state>AL</state>
        <zip>08112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeriy Cheshuk, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

